Risks related to cytostatic exposure for nursing staff;Risques liés à l'exposition aux cytostatiques pour le personnel soignant

Presse Medicale

Volumn 30, Issue 32, 2001, Pages 1596-1600

  Deschamps, F J ^a   Marinutti Liberge, V ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADRIALASTINE; AMSACRINE; AZACITIDINE; AZATHIOPRINE; BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORAMINOFENE; CHLORMETHINE; CHLORNAPHAZINE; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; HYDRAZINE; LOMUSTINE; MELPHALAN; MITOMYCIN C; PREDNISONE; PROCARBAZINE; SEMUSTINE; STREPTOZOCIN; THIOTEPA; TREOSULFAN; UNINDEXED DRUG; VINCRISTINE SULFATE;

DRUG CARCINOGENICITY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; HUMAN; MUTAGENICITY; NURSING STAFF; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; REVIEW; TERATOGENICITY;

ANTINEOPLASTIC AGENTS; HEALTH PERSONNEL; HUMANS; OCCUPATIONAL EXPOSURE; POPULATION SURVEILLANCE; RISK FACTORS;

EID: 0035802707     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Les médicaments cytostatiques en milieu de soins
2. Precautionary measures in the preparation of antineoplastics
3. Hypersensibilité immédiate et antimitotiques. Nécessité de la protection du personnel soignant
4. Risques encourus par les personnels soignants manipulant des cytostatiques
5. Advance reactions to AMSA in medical personnel
6. Acute occupational exposure to antineoplastic agents
7. Handling of cytotoxic drugs: Governmental regulations and pratical solutions
8. Allergie respiratoire professionnelle aux sels de platine
9. Asthme au platine
10. Liver damage in nurses handling cytostatic agents
11. Risque professionnel encouru par les médecins et les chercheurs vis-à-vis des cancers
12. Risque d'avortement spontané et préparation des chimiothérapies anticancéreuses chez les infirmières
13. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses
14. Maternal occupational risk factors for oral clefts. Occupational exposure and congenital malformation working group
15. Occupational exposure to antineoplastic agents: Self-reported miscarriages and stillbirths among nurses and pharmacists
16. Spontaneous abortions and malformations in the offspring of nurses exposed to anaeshetic gases, cytostatics drugs and other potential hazards in hospitals, based on registered information of outcome
17. Occupational exposure to antineoplastic agents and self-reported infertility along nurses and pharmacists
18. Ectopic pregnancy and occupational exposure to antineoplastic drugs
19. Occupational exposure to cyclophosphamide
20. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide
21. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers
22. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: Urinary excretion and cytogenetics studies
23. Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics
24. Risk assessment concerning hospital personnel participating in the preparation and administration of antineoplastic drugs
25. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate
26. Determination of methotrexate in human urine at trace levels by solid phase extraction and high-performance liquid chromatography/tandem mass spectrometry
27. Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs urinary mutation assays and urinary platinum as markers of absorption
28. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs
29. Urinary thioether excretion in nurses handling cytotoxic drugs
30. Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil
31. Mutagenicity in urine of nurses handling cytostatic drugs
32. Monitoring exposure of hospital personnel handling cytostatic drugs and contaminated materials
33. Exposition aux produits chimiques génotoxiques. Marqueurs biologiques pour la surveillance des salariés
34. Risques liés à la manipulation des médicaments cytostatiques
35. Nurses' and pharmacists' exposure to antineoplastic drugs: Finding from industrial hygiene scans and urine mutagenicity tests
36. Cytogenetic consequences after occupational exposure to antineoplasic drugs
37. Increased sister chromatid exchange frequencies in lymphocytes of nurses handling cytostatic drugs
38. Human effect monitoring in cases of occupational exposure to antineoplastic drugs: A method comparison
39. Long-term monitoring of sister chromatid exchanges and micronucleus frequencies in pharmacy personnel occupationally exposed to cytostatic drugs
40. Surveillance biogénotoxicologique des infirmières manipulant des cytostatiques
41. Measurement of surface contamination by certain antineoplastic drugs using high-performance liquid chromatography: Applications in occupational hygiene investigations in hospital environments
42. High-performance liquid chromatography of methotrexate for environmental monitoring of surface contamination in hospital departments and assessment of occupational exposure
43. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States
44. Determination of methotrexate in environmental samples by solid phase extraction and high performance liquid chromatography: Ultraviolet or tandem mass spectrometry detection?
45. Les médicaments cytostatiques en milieu de soins. Recommandations pour la prévention des risques professionnels